Līva, a devoted mother of two young daughters, has been diagnosed with advanced breast cancer that has progressed to stage four after initially being recognized as treatable. Despite her extensive treatment, including immunotherapy and chemotherapy over the year, Līva's cancer mutated and became resistant to the prescribed medications, leading her to an alarming conclusion that she has minimal chances of prolonged survival. In her painful journey, she has learned that the disease has metastasized, affecting multiple organs, and she is now in a desperate situation seeking effective treatment options.

In light of her deteriorating condition, doctors informed Līva about potential medications that could help extend her life, but the financial burden of these treatments is overwhelming. The state's refusal to provide compensation for her medication adds to the distressing reality she faces; her oncologist's words resonate deeply, indicating that Līva must 'pay for time to live'. This translates to an exorbitant cost of €8,000 per month, a sum that is unattainable for her, especially as a single parent with limited resources.

The situation raises significant questions regarding healthcare policies and the accessibility of life-saving treatments for patients like Līva in Latvia. The current framework poses challenges for individuals battling severe health crises, highlighting a critical need for reform to ensure that financial disparities do not dictate one’s access to necessary care. Patients in similar situations may find themselves facing ethical dilemmas inherent in healthcare systems that fail to support vulnerable individuals adequately.